Holen Sie sich die Stockscreener-App
1.80
0.00%
0.00
Handel nachbörslich:
1.82
0.02
+1.11%
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Immuneering Corp. Reports Q3 Loss, Highlights Progress - TipRanks
Immuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 6.7% - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug - Yahoo Finance
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Uncovering the Potential of Immuneering Corp (IMRX) Stock - The InvestChronicle
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
FDA grants orphan drug status to Immuneering's cancer treatment - Investing.com
FDA grants orphan drug status to Immuneering's cancer treatment By Investing.com - Investing.com Canada
Financial Health Check: Examining Immuneering Corp (IMRX)’s Key Ratios - The Dwinnex
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer - StockTitan
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World
Renaissance Technologies LLC Takes Position in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
IMRX’s Stochastic Averages Dip: Analyzing Immuneering Corp’s Stock Performance - The InvestChronicle
Marshall Wace LLP Makes New Investment in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
The time has not yet come to remove your chips from the table: Immuneering Corp (IMRX) - SETE News
A stock that deserves closer examination: Immuneering Corp (IMRX) - US Post News
Immuneering Corp’s Market Journey: Closing Strong at 2.47, Up 4.22 - The Dwinnex
Immuneering stock maintains Outperform rating on positive prospects - Investing.com
How does Immuneering Corp (IMRX) change from a tortoise to a hare? - SETE News
Understanding the Risks of Investing in Immuneering Corp (IMRX) - Knox Daily
Immuneering Corp (IMRX) Stock: A Year of Decreases and Increases - The InvestChronicle
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX)’s stock chart: A technical perspective - US Post News
Ratio Revelations: Immuneering Corp (IMRX)’s Financial Metrics in the Spotlight - The Dwinnex
Biotech Surges Premarket Following Positive Phase 2a Observations - MSN
Immuneering Corp (IMRX) Recovers 161.00% From Low: Sitting In The Catbird Seat? - Stocks Register
Immuneering Corp [IMRX] stock for 1,160,181 USD was sold by Cormorant Asset Management, LP - Knox Daily
You might want to take a look at Immuneering Corp (IMRX) now - SETE News
Immuneering Corp [IMRX] Insider Cormorant Asset Management, LP sells 400,000 Shares - Knox Daily
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
Immune Price Drop Is An Entry Opportunity - Top Buzz Times
IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle
Analytical Overview: ImmunityBio Inc (IBRX)’s Ratios Tell a Financial Story - The Dwinnex
Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex
Inflection Point Acquisition Corp. II (NASDAQ:IPXX) Shares Bought by Berkley W R Corp - MarketBeat
Armored car company tires reverse domain name hijacking - Domain Name Wire
Daily Market Movement: Immuneering Corp (IMRX) Sees a -10.59 Decrease, Closing at 2.87 - The Dwinnex
IOH announces stock split to enhance investor participation - Telecompaper EN
Impax Asset Management Group (LON:IPX) Stock Passes Below Fifty Day Moving Average of $383.00 - MarketBeat
Rhumbline Advisers Acquires Shares of 67,184 Immunome, Inc. (NASDAQ:IMNM) - Defense World
ImpediMed Expands U.S. Market Coverage - TipRanks
IDP Education Reports Substantial Shareholder Changes - TipRanks
Analysts review Immunome Inc’s rating - Knox Daily
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
IMAX Co. (NYSE:IMAX) Shares Sold by Rhumbline Advisers - Defense World
Immuneering Corp Inc. (IMRX) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Ipsen: Parvus AM Europe Ltd falls below 5% of voting rights - Marketscreener.com
Are Immuneering Corp (IMRX) shares a good deal now? - US Post News
IPCA Laboratories Looking to Consolidate US Generics Business; Shares Gain - EquityPandit
IMI plc Advances Share Buyback with J.P. Morgan - TipRanks
Ipca Laboratories to consider consolidaton of US generics business - CNBCTV18
International Public Partnerships Buys Back Shares - TipRanks
TIFF 2024: Ick Review - keithlovesmovies.com
Integrated BioPharma (OTCMKTS:INBP) Posts Quarterly Earnings Results - Defense World
Acadian Asset Management LLC Has $61,000 Holdings in IMAX Co. (NYSE:IMAX) - Defense World
Max Rosett Sells 14,380 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock - MarketBeat
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt (NASDAQ:IBRX) - Seeking Alpha
Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett Sells 14,380 Shares - Defense World
Immunome CFO sells shares valued at over $230,000 By Investing.com - Investing.com Canada
Immunome CFO sells shares valued at over $230,000 - Investing.com
Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024 - StockTitan
Ick Review — TIFF 2024 - CGMagazine
IMI (LON:IMI) Stock Passes Above Two Hundred Day Moving Average of $1,805.79 - Defense World
Indofarma Corruption Case Rp371 Billion, Former President Director Allegedly Buys Fictitious Medical Devices - VOI.ID
Staff Of Erick Thohir Regarding Ex-Director Of Indofarma Becomes A Suspect: Part Of Cleaning Up SOEs - VOI.ID
State Loss Of IDR 371 Billion, DKI Prosecutor's Office Explains The Role Of Three Corruption Suspects Of PT Indofarma - VOI English
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):